SOURCE: Critical Outcome Technologies Inc. (COTI)

Critical Outcome Technologies Inc. (COTI)

June 01, 2016 08:30 ET

Critical Outcome to Present at International Li-Fraumeni Syndrome Conference and at BIO International Convention

LONDON, ON--(Marketwired - June 01, 2016) - Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") announced today that the Company has been invited to present at the upcoming International Li-Fraumeni Syndrome ("LFS") Conference in Columbus, Ohio. The Company will also be presenting at the annual BIO International Convention in San Francisco, California.

The Company's Chief Executive Office, Dr. Wayne Danter, is scheduled to give a podium presentation at the International LFS Conference on Thursday, June 2nd from 2:15 to 2:40 p.m. Dr. Danter's presentation scheduled for June 2nd is titled, "COTI-2: The discovery and development of a clinical stage small molecule for targeting carriers with p53 mutations."

The Critical Outcome team will also be attending the BIO International Convention, with Dr. Danter scheduled to make two presentations during the convention as follows:

  • Monday, June 6th, at 2 p.m. -- Dr. Danter will make a presentation about ROSALIND, the Company's recently launched smart data platform designed to provide better personalized treatment options to cancer patients based on their tumor's genetic profile.
  • Wednesday, June 8th, at 2 p.m. -- Dr. Danter will be presenting an update on COTI-2, the Company's clinical stage, novel small molecule activator of misfolded mutant p53 proteins.

About the International LFS Conference

The 2016 International LFS Conference & The 3rd Annual LiFE Consortium and LFS Association Conference presented by Soccer for Hope will be held June 1 through 3, 2016, under the auspices of the Division of Hematology, Oncology and BMT of Nationwide Children's Hospital and The Ohio State University, in Columbus, Ohio.

Thanks to the leadership of Dr. David Malkin of Toronto Sick Children's Hospital, Co-Chair of the Scientific Committee, the LFSA can confirm that 30 of the world's foremost physicians and scientists in the fields of cancer genetics and LFS research will present at this conference. More than 250 physicians, scientists, specialists, and family members affected by LFS from across the globe are expected to participate.

About the BIO International Convention

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The Convention brings together established and emerging leaders in the global biotechnology and pharmaceutical industry.

About Critical Outcome Technologies Inc.

COTI is a clinical stage biopharmaceutical company advancing the treatment of cancer through targeted therapeutics. The Company's lead compound, COTI-2, has a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. The initial therapeutic indication is in gynecologic cancers, which includes ovarian, cervical, and endometrial cancers; treatment of patients in a Phase 1 clinical trial began at MD Anderson Cancer Center in February 2016. The Company has secured orphan drug status for the ovarian indication in the U.S. and is planning additional studies in other cancer indications such as head and neck, Li-Fraumeni Syndrome, and acute myelogenous leukemia, based upon more than ten animal xenograft models showing both single and combination agent activity of COTI-2 with other leading cancer drugs. Preclinical data provides evidence to suggest a potentially dramatic change in the treatment of cancers with mutations of the p53 gene.

Follow @CriticalOutcome on Twitter or visit our award winning website: www.criticaloutcome.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information